ENHANCING THE IMMUNOGENICITY AND EFFICACY OF VECTORED VACCINES

Adrian Hill, University of Oxford, United Kingdom

Adrian Hill’s career as a scientist is defined by a single-minded passion: to develop a vaccine against malaria. It has driven him ever since he was a young geneticist in the late 1980s when he traveled several times to a hospital in The Gambia to study the disease.

“There were few doctors, and at times no antimalarial drugs,” says Hill, director of the Jenner Institute at the University of Oxford. “You could only watch as children died.” A vaccine to protect against the malaria parasite, *Plasmodium falciparum*, ranks as one of the most important goals in global public health. The mosquito-borne infection kills more than 600,000 children a year in Africa. And 25 years after he came face to face with the human tragedy caused by the parasite, Hill and his colleagues have created one of the most promising vaccine candidates.

In preliminary clinical trials with healthy volunteers, Hill’s experimental vaccine has prevented the onset of malaria infection and disease in 20 percent of test subjects. A subsequent larger trial in 121 men in Kenya found that the vaccine reduced the risk of infection by 67 percent.

As impressive, it also results in the elimination by the immune system of more than 90 percent of liver cells infected by the malaria parasite. By eliminating cells already infected, the vaccine reduces the amount of parasites that can exit the liver and cause life-threatening complications.

The response in liver cells is important because once the malaria parasite enters the bloodstream after a mosquito bite it races to the liver. There it infects the liver cells and uses them as a factory to produce swarms of the pathogen, which swamp the bloodstream, killing red blood cells and causing severe anemia. Under these conditions, children often die.

The vaccine’s progress has been supported in a large part over the past decade by a $10 million grant from the Bill & Melinda Gates Foundation’s Grand Challenges in Global Health program, building on about $20 million of support from the Wellcome Trust, the UK Medical Research Council and the European Commission. The vaccine is the first of its kind to induce the human immune system to produce a potent cellular immunity attack by CD8 T cells.
that are capable of identifying liver cells infected by the parasite and destroying them before they can unleash an army of pathogens into the bloodstream.

“We’ve been good at firing up one arm of the immune system that produces antibodies,” Hill says. “But what we realized as far back as the early 1990s is that we may need the other arm, cellular immunity, to protect against viruses like HIV, as well as tuberculosis and malaria.” Antibodies are proteins that patrol the bloodstream and lock onto microbe particles and sweep them up. Since antibodies alone may not be able to wipe out an entire population of parasites that volunteers, the DNA of a protein fragment of the parasite. The idea was that the DNA contained in a saline solution would stir the body’s cellular machinery to convert the genetic material into the protein fragment—called an antigen—that would trick the immune system into reacting as if a pathogen invasion was underway. In a two-shot approach Hill developed by 2000, volunteers were first given the DNA injection to kick-start an immune system reaction. This “prime” inoculation was followed by a second booster shot of the same DNA inserted into modified vaccinia virus Ankara (MVA). Following years of experiments, Hill had found that using the two-shot “prime-boost” vaccine, and then were exposed to five bites from mosquitoes carrying the malaria parasite. Hill and his colleagues analyzed the subjects’ blood to determine if each new iteration of the vaccine spurred greater amounts of T cells than the previous versions had. As the T cells alone were never fully protective, infected volunteers were then treated with antimalarial drugs so they didn’t become sick.

In this way, after comparing many antigens both in the lab and in field studies of people naturally exposed to malaria in Africa, by 2001 Hill and his laboratory found that the best available T cell-inducing antigen was one called TRAP, a molecule from the parasite that appeared in liver cells after they were infected. Liver cells naturally expose TRAP to the immune system to trigger a protective T cell attack, but the amounts of T cells generated naturally by humans this way are rarely enough to prevent disease. By delivering the fragment first via the DNA in saline and then via the DNA contained inside the MVA vector, Hill hoped to stimulate a large enough number of T cells to be protective.

In 2003, the first field trial of the “prime-boost” vaccine in almost 300 volunteers in The Gambia prompted a T-cell response. But after 11 weeks, the vaccinated adults weren’t any less likely to develop malaria than a control group that had not been vaccinated.5 “The good

---

“Producing potent cellular immunity by immunization has been a 20-year obsession for me,” Hill says.

infest the blood derived from the bite of an infected mosquito, any amount of the microbe that reaches the liver can be enough to cause disease. To prevent disease, therefore, the body may require a second, back-up response from cellular immunity—generated T cells.

“Producing potent cellular immunity by immunization has been a 20-year obsession for me,” Hill says. Hill hit on a strategy by the late 1990s to induce cellular immunity to target an infected liver by administering, via injection into human

the MVA strain as a vector containing the antigen’s DNA spurred an additional potent cellular immune response.4

By this time, Hill had tested numerous parasite proteins to determine which fragment of the pathogen was best at eliciting just the right T cells. As important, he also made use of a fast and safe way to test in a small number of healthy volunteers whether each new version improved the cellular response. The volunteers were recruited at the Jenner Institute campus in Oxford, where they first were administered
news is we got a T-cell response in nearly everyone,” Hill says. “The bad news was—it wasn’t enough.”

At this time, Hill sought the Grand Challenges in Global Health grant to bolster his laboratory with graduate and post-graduate researchers to search for additional components, called adjuvants, that if added to the vaccine would significantly increase the numbers of T cells induced by the vaccine. “The Grand Challenges in Global Health grant allowed us to take a step back and ask what’s really needed to make a major step forward in making a powerful, potent cellular immune response, going back to the drawing board if you like and trying a whole variety of new approaches,” Hill says. “There was a huge risk this would yield absolutely nothing.”

Using funds from the Grand Challenges in Global Health five-year grant, Hill’s laboratory mined the human genome, eventually identifying more than 70 different adjuvant candidates, and testing even more combinations of adjuvants and antigens. The laborious

Adrian Hill (right) discusses an experiment with a colleague in the lab. They are focusing on improving vaccines for malaria, HIV and tuberculosis.
and tedious task of testing version after version finally paid off. “In the end we found two approaches that produce a very potent cellular immune response,” Hill says. “Before we started we had no idea which two that would be.”

The Hill research group then added the best of the adjuvants they had uncovered during the years of laboratory experiments to their TRAP malaria vaccine and moved forward to clinical testing of the adjuvants.

While the Grand Challenges in Global Health grant supported this laboratory research, the clinical tests in volunteers at the Jenner Institute and in field trials that assessed T-cell production of a sequence of new vaccine approaches were supported with grants from the UK Medical Research Council, the European Commission, the European Vaccine Initiative and the Wellcome Trust.

But two years into the five-year grant, “Adrian hadn’t made the progress we had hoped,” says Stephanie James, the grant’s project manager at the Foundation for the National Institutes of Health. Hill was eliciting T cells, but not enough to be protective. “There was a lot of searching, searching, searching.”

Hill himself realized he needed to find better vaccine vectors to contain the TRAP antigen and stimulate a more potent immune response than the DNA alone. Since viruses can naturally induce a strong immune response on their own, a weakened virus carting the antigen into
the body very efficiently would likely improve T-cell production, he reasoned. Collaborating with scientists from the University of Pennsylvania he had found that particular viruses from chimpanzees showed real promise as vectors but these were not available for clinical development. The answer finally came in 2006, after Riccardo Cortese, chief executive and founder of Okairos AG, a Swiss-based biotech company, traveled to the Jenner Institute to present evidence that his company had independently developed a similar virus vector that might work.

Merck, the U.S. pharmaceutical company, previously had used a weakened adenovirus, a virus that causes respiratory and gastrointestinal ills in people, as a vector to elicit potent T cells in an experimental AIDS vaccine. The adenovirus was employed because it naturally triggers T cells, and because researchers had figured out relatively simple ways to insert antigen genes into it. Hill was reluctant to use human adenoviruses as vaccine carriers in Africa because people there were frequently exposed to these, so their protection would be blunted.

However, Okairos, under Cortese’s direction, had a different solution: a similar adenovirus that infected chimpanzees. Cortese had developed the approach at a laboratory in Rome owned by Merck. When Merck decided not to pursue chimpanzee virus research, Cortese created Okairos to develop the antigen-carrying platform himself. Between 2007 and 2010, Hill and Okairos working

“Adrian’s contribution has been to show in clinical trials that inducing T cells against the parasite can be very powerful,” says Ashley Birkett, director of the PATH Malaria Vaccine Initiative.

In addition to showing that the vaccine reduced the risk of infection by 67 percent in the study involving 121 Kenyan men,\(^1\) Hill’s team estimated that the vaccine killed more than 90 percent of infected liver cells.\(^1\)

“Adrian’s contribution has been to show in clinical trials that inducing T cells against the parasite can be very powerful,” says Ashley Birkett, director of the PATH Malaria Vaccine Initiative, which promotes research in the field. “As of now, it’s one of the two most advanced approaches we have.”

In June 2013, the British pharmaceutical company, GlaxoSmithKline (GSK) Plc, bought Okairos in a $325 million deal little noticed in the financial press. In the world of vaccine research, the acquisition was big news because it validated Hill’s prime-boost regimen as a way to spur T cells. GSK says it plans to use the chimp-adeno technology as the foundation for vaccines against cancer, tuberculosis, hepatitis C, HIV and also malaria. The Jenner Institute is also progressing its own HIV and TB vaccines employing
THE SCIENCE:
Inducing protective CD8+ T cell-immunity to malaria by a heterologous prime-boost vaccination approach

Adrian Hill and colleagues are harnessing cellular immunity to boost malaria vaccine efficacy. They analyzed different approaches to induce potent antigen-specific CD8+ T cells targeting liver-stage malaria parasites, which are thought to be particularly vulnerable to immune attack. CD8+ T cells producing interferon gamma (IFN-γ) identify and kill host cells infected with pathogens such as Plasmodium. CD8+ T-cell responses can be induced by delivering liver-specific malaria antigens such as threomospondin-related adhesion protein (TRAP) from P. falciparum with replicating and non-replicating viral vectors including human adenoviruses and the poxvirus, modified vaccinia virus Ankara (MVA). However, protection may be short-lived, and in many people, pre-existing neutralizing antibodies against the commonly used human adenovirus serotypes impair the T-cell response.

To enhance protection they developed a heterologous prime-boost regimen involving sequential administration of an adenovirus from chimpanzees (ChAd), which was shown to elicit a safe and potent protective immune response in humans, followed by MVA, both carrying the modified malaria antigen, ME-TRAP (TRAP fused to 20 mainly CD8+ T-cell epitopes from pre-erythrocytic antigens). With this approach they could induce better immune responses and longer-term sterile protection against malaria in mice, rhesus macaques, and humans. In the human Phase Ia trial, their prime-boost approach using the chimpanzee adenovirus provided a significant protection rate against malaria (3 out of 14 vaccinees were sterilely protected, one of whom remained protected for 8 months), which was higher than in all other comparable trials, and five developed malaria later than the unvaccinated controls. This sterile protection and delayed latency correlated with the frequency of monofunctional IFN-γ-producing CD8+ T cells and not with antibodies, which was the first report of a CD8+ T cell correlate of vaccine-induced protection in humans. This work paves the way for CD8+ T-cell-based vaccines for many other infectious and non-infectious diseases.

a different chimp-adeno vector developed in-house.

In a separate yet related development, Hill has recently begun testing in healthy volunteers a combination of the chimp-adeno vaccine with GSK’s most recent version of its long-studied antibody-producing RTS.S vaccine. In several large trials in Africa, RTS.S has reduced the incidence of a malaria infection by as much as 30 to 50 percent. “It’s conceivable the two vaccines together might protect as many as 70 percent of recipients,” says Ripley Ballou, a GSK official involved in the RTS.S project.

Finally, in an unexpected bonus, Hill’s team has helped create a version of the vaccine that might not need to be refrigerated, often a challenge in getting vaccines to distant locales in poor countries where resources are limited. “The technology is based on a mixture of vaccine with simple sugars that is then dried on a thin paper membrane. That makes the vaccines thermostable, so they are able to stay potent at 37 degrees centigrade, human body temperature, for 12 months,” Hill says. “That’s unprecedented.”

Hill is optimistic that the combination of the chimp-adeno with MVA and RTS.S vaccines has the best chance yet of being the first “high-efficacy deployable malaria vaccine,” he says. “If we do get to the finish line, the Grand Challenges in Global Health program will have been a significant contributor.”
REFERENCES:


